Submitted:
03 January 2025
Posted:
06 January 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design and Setting
2.2. Measures and Outcomes
2.3. Scoring Systems
2.4. Statistical Analysis
3. Results
3.1. Characteristics of Patients
3.2. Prediction of 14-Day and 30-Day Mortality, and ICU Admission
3.3. Exploratory Analysis Using the Youden Index
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Reinhart K, Daniels R, Kissoon N, Machado FR, Schachter RD, Finfer S. Recognizing Sepsis as a Global Health Priority - A WHO Resolution. N Engl J Med. 2017, 377, 414–417. [Google Scholar] [CrossRef] [PubMed]
- Global Sepsis Alliance. WHA adopts resolution on sepsis [Internet]. Jena, Germany: Global Sepsis Alliance; 2017.
- Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017, 43, 304–377. [Google Scholar] [CrossRef] [PubMed]
- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016, 315, 801–10. [Google Scholar] [CrossRef] [PubMed]
- INSTITUTO LATINO AMERICANO DE SEPSE. IMPLEMENTAÇÃO DE PROTOCOLO GERENCIADO DE SEPSE. PROTOCOLO CLÍNICO: Atendimento ao paciente adulto com sepse/ choque séptico. INSTITUTO LATINO AMERICANO DE SEPSE, Agosto de 2017.
- Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018, 44, 925–928. [Google Scholar] [CrossRef] [PubMed]
- Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Møller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021, 47, 1181–1247. [Google Scholar] [CrossRef]
- Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011, 52, e56–93. [Google Scholar] [CrossRef] [PubMed]
- Wang C, Xu R, Zeng Y, Zhao Y, Hu X. A comparison of qSOFA, SIRS and NEWS in predicting the accuracy of mortality in patients with suspected sepsis: A meta-analysis. PLoS One. 2022, 17, e0266755. [Google Scholar]
- Garbero RF, Simões AA, Martins GA, Cruz LVD, von Zuben VGM. SOFA and qSOFA at admission to the emergency department: Diagnostic sensitivity and relation with prognosis in patients with suspected infection. Turk J Emerg Med. 2019, 19, 106–110. [Google Scholar] [CrossRef] [PubMed]
- Ruangsomboon O, Boonmee P, Limsuwat C, Chakorn T, Monsomboon A. The utility of the rapid emergency medicine score (REMS) compared with SIRS, qSOFA and NEWS for Predicting in-hospital Mortality among Patients with suspicion of Sepsis in an emergency department. BMC Emerg Med. 2021, 21, 2. [Google Scholar]
- Oduncu AF, Kıyan GS, Yalçınlı S. Comparison of qSOFA, SIRS, and NEWS scoring systems for diagnosis, mortality, and morbidity of sepsis in emergency department. Am J Emerg Med. 2021, 48, 54–59. [Google Scholar] [CrossRef] [PubMed]
- Goulden R, Hoyle MC, Monis J, Railton D, Riley V, Martin P, Martina R, Nsutebu E. qSOFA, SIRS and NEWS for predicting inhospital mortality and ICU admission in emergency admissions treated as sepsis. Emerg Med J. 2018, 35, 345–349. [Google Scholar] [CrossRef] [PubMed]
- Usman OA, Usman AA, Ward MA. Comparison of SIRS, qSOFA, and NEWS for the early identification of sepsis in the Emergency Department. Am J Emerg Med. 2019, 37, 1490–1497. [Google Scholar] [CrossRef] [PubMed]
- Liu VX, Lu Y, Carey KA, Gilbert ER, Afshar M, Akel M, Shah NS, Dolan J, Winslow C, Kipnis P, Edelson DP, Escobar GJ, Churpek MM. Comparison of Early Warning Scoring Systems for Hospitalized Patients With and Without Infection at Risk for In-Hospital Mortality and Transfer to the Intensive Care Unit. JAMA Netw Open. 2020, 3, e205191. [Google Scholar] [CrossRef]

| Variáveis | Total (n=311) | 14-day mortality (n=80) |
30-day mortality (n=112) |
ICU admission (n=154) |
|---|---|---|---|---|
| Average age, years (±SD) | 58.4 (±15.3) | 57.6 (±14.6) | 59.7 (±14.4) | 58.6 (±15) |
| Sex male | 153 (49.2%) | 94 (47.2%) | 59 (52.7%) | 87 (56.5%) |
| Sepsis diagnosis (n, %) | ||||
| Sepsis | 232 (74.6%) | 88 (82.9%) | 67 (59.8%) | 86 (55.8%) |
| Septic shock | 79 (25.4%) | 36 (17.1%) | 45 (40.2%) | 68 (44.2%) |
| Underlying diagnosis (n, %) | ||||
| Acute leucemias | 50 (16.1%) | 18 (22.5%) | 23 (20.5%) | 29 (18.8%) |
| Lymphomas | 77 (24.8%) | 17 (21.3%) | 26 (23.2%) | 32 (20.8%) |
| Multiple myeloma | 62 (19.9%) | 13 (16.3%) | 22 (19.6%) | 31 (20.1%) |
| Chronic leucemias | 45 (14.5%) | 12 (15%) | 16 (14.3%) | 21 (13.6%) |
| Others | 77 (24.8%) | 20 (25%) | 25 (22.3%) | 41 (26.6%) |
| Infection site (n, %) | ||||
| Pulmonary | 158 (50.8%) | 38 (47.5%) | 57 (50.9%) | 81 (52.6%) |
| Urinary tract | 14 (4.5%) | 2 (2.5%) | 3 (2.7%) | 5 (3.2%) |
| Intra-abdominal | 57 (18.3%) | 27 (33.8%) | 31 (27.7%) | 34 (22.1%) |
| Bloodstream | 24 (7.7%) | 4 (5%) | 6 (5.4%) | 12 (7.8%) |
| Skin and soft tissue | 8 (2.6%) | 0 (0%) | 0 (0%) | 3 (1.9%) |
| FUO | 39 (12.5%) | 8 (10%) | 12 (10.7%) | 13 (8.4%) |
| Others | 11 (3.5%) | 1 (1.3%) | 3 (2.7%) | 6 (3.9%) |
| Scoring systems (n, %) | ||||
| SIRS≥2 | 261 (83.9%) | 72 (90%) | 98 (87.5%) | 140 (90.9%) |
| qSOFA≥2 | 123 (39.5%) | 48 (60%) | 63 (56,3%) | 88 (57.1%) |
| MEWS≥4 | 244 (78.5%) | 67 (83.8%) | 94 (83.9%) | 130 (84.4%) |
| SOFA, mean (±SD) | 4.9 (±3.2) | 6.8 (±3.6) | 6.6 (±3.5) | 6.4 (±3.4) |
| qSOFA ≥2 | SRIS ≥2 | MEWS ≥4 | |
| 30-day mortality | |||
| Sensitivity % (95%CI) | 56.3 (46.6 - 65.6) | 87.5 (79.9 - 93.0) | 83.9 (75.8 - 90.2) |
| Specificity % (95%CI) | 68.8 (63.0 - 76.1) | 18.1 (13.0 - 24.2) | 24.6 (18.8 - 31.2) |
| AUROC (cutoff) (95%CI) | 0.634 (0,578 - 0,688) | 0.526 (0,469 - 0,583) | 0.585 (0,528 - 0,640) |
| Positive likelihood ratio (95%CI) | 1.87 (1.43 - 2.44) | 1.07 (0.97 - 1.18) | 1.11 (0.99 - 1.25) |
| Negative likelihood ratio (95%CI) | 0.63 (0.50 - 0.79) | 0.69 (0.39 - 1.22) | 0.65 (0.40 - 1.06) |
| Positive predictive value % (95%CI) | 50.4 (43.8 – 56.9) | 37.5 (35.3 – 39.8) | 38.5 (35.9 – 41.2) |
| Negative predictive value % (95%CI) | 73.7 (69 – 77.9) | 72 (59.2 – 82) | 73.1 (62.5 – 81.6) |
| 14-day mortality | |||
| Sensitivity % (95%CI) | 60 (48.4 - 70.8) | 90 (81.2 - 95.6) | 83.5 (73.8 - 91.1) |
| Specificity % (95%CI) | 67.5 (61.1 - 73.5) | 18.2 (13.4 - 23.8) | 23.4 (18.1 - 29.4) |
| AUROC (cutoff) (95%CI) | 0.632 (0.576 - 0.686) | 0.552 (0.495 - 0.608) | 0.601 (0.544 - 0.656) |
| Positive likelihood ratio (95%CI) | 1.85 (1.43 - 2.39) | 1.10 (1.00 - 1.21) | 1.09 (0.97 - 1.23) |
| Negative likelihood ratio (95%CI) | 0.59 (0.45 - 0.79) | 0.55 (0.27 - 1.12) | 0.70 (0.40 - 1.20) |
| Positive predictive value % (95%CI) | 39 (33 – 45.2) | 27.6 (25.7 – 29.5) | 27.4 (25.1 – 29.9) |
| Negative predictive value % (95%CI) | 83 (78.6 – 86.6) | 84 (72.1 – 91.5) | 80.4 (70.4 – 87.6) |
| ICU admission | |||
| Sensitivity % (95%CI) | 57.1 (48.9 - 65.1) | 90.9 (85.2 - 94.9) | 84.4 (77.7 - 89.8) |
| Specificity % (95%CI) | 77.7 (70.4 - 84.0) | 22.98 (16.6 - 30.3) | 27.4 (20.6 - 35.1) |
| AUROC (cutoff) (95%CI) | 0.713 (0,659 - 0,763) | 0.571 (0,514 - 0,626) | 0.629 (0,573 - 0,683) |
| Positive likelihood ratio (95%CI) | 2.56 (1.86 - 3.54) | 1.18 (1.07 - 1.30) | 1.16 (1.03 - 1.31) |
| Negative likelihood ratio (95%CI) | 0.55 (0.45 - 0.67) | 0.40 (0.22 - 0.71) | 0.57 (0.36 - 0.89) |
| Positive predictive value % (95%CI) | 71.5 (64.5 – 77.6) | 53.6 (51.2 – 56.1) | 53.3 (50.3 – 56.2) |
| Negative predictive value % (95%CI) | 64.9 (60.2 – 69.3) | 72 (59.2 – 82.1) | 64.2 (53.4 – 73.7) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).